Business
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the second annual Oncology Venture, Innovation, and Partnering Summit being held September 29-30, 2025, at the Westin Boston Seaport in Boston, MA. Eric P
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TVVsA9n31LT1YQqkVdlDAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the second annual Oncology Venture, Innovation, and Partnering Summit being held September 29-30, 2025, at the Westin Boston Seaport in Boston, MA.","length":498,"tagName":"p"},{"type":"text","content":"Eric Poma, Ph.D., Chief Executive Officer, will participate in a fireside chat with Dr. Aydin Huseynov, Managing Director and Senior Analyst at Ladenburg Thalmann, on the intersection of science and capital to develop and advance effective cancer treatments on September 30, 2025, at 10:10 a.m. E.T. Dr. Poma’s presentation will highlight Calidi’s RedTail platform, which is engineered to protect virus from immune clearance and induce tumor lysis and deliver potent therapeutic genetic medicines to metastatic sites through systemic administration.","length":549,"tagName":"p"},{"type":"text","content":"Dr. Poma will be available to participate in one-on-one meetings with participants registered to attend the conference.","length":119,"tagName":"p"},{"type":"text","content":"About Calidi Biotherapeutics","length":28,"tagName":"p"},{"type":"text","content":"Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technolog...